Unlikely new problem emerges for immunotherapy trials

4 July 2017

Given the prevalence of cancer, not having enough patients to test the potential cancer treatments of tomorrow might seem an unlikely problem.

But according to The Financial Times, pharma execs are concerned that some companies might struggle to fill their trials for immunotherapies because of the surge in the number of such studies.

Almost all of the world’s leading pharma companies are trying to come up with the next immuno-oncology blockbuster, seeking to capitalize on a market which GBI Research expects be worth $76 billion by 2022, having seen the success being achieved already by the likes of Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) in this field.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK